The build-up of stock of stable integrated proviruses overtime explains the difficulty in reducing HIV-1 DNA levels when treatment is initiated at the chronic stage of the infection.
In: Journal of virus eradication, Jg. 9 (2023-12-09), Heft 4, S. 100357
Online
academicJournal
Zugriff:
Background: Understanding factors affecting the size and the evolution of the HIV reservoir is essential for the development of curative strategies. This study aimed to assess the impact of antiretroviral therapy (ART) initiated during primary infection (PHI) vs chronic infection (CHI) on the levels and dynamics of integrated HIV-1 DNA, a biomarker of viral persistence.
Methods: Integrated and total HIV-1-DNA were measured in the blood of 92 patients treated during PHI (early group) and 41 during CHI (deferred group), at diagnosis, ART initiation, and 12-24 months on treatment.
Results: On ART, detectable (>1.78 log 10 copies/10 6 PBMCs) integrated HIV-1 DNA levels were significantly lower in the early vs deferred group (2.99 log 10 vs 3.29 log 10, p = 0.005). The proportion of undetectable integrated HIV-1 DNA tended to be higher in the early group vs deferred group (61 % vs 46 %; p = 0.133).
Conclusion: Treatment initiated at PHI limits the levels of integrated HIV-1 DNA in blood. However, initiating treatment at CHI does not allow reaching such low levels in most patients, probably because the stable proviruses at that stage are present in the less prone to elimination long-lived cells. Thus, early ART could provide an opportunity to preparing for functional cure and eradication strategies.
Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: V.A.-F. has received grants (to her institution) from the 10.13039/501100003323ANRS, 10.13039/100010877ViiV Healthcare and the MSD AVENIR foundation and honoraria and travel grants from 10.13039/100010877ViiV Healthcare and 10.13039/100005564Gilead Sciences, for participation in educational programs and conferences. A.C. reports grants from 10.13039/100005564Gilead Sciences, 10.13039/100010877ViiV Healthcare and Janssen. C.C. reports grants from 10.13039/100010877ViiV Healthcare and 10.13039/100005564Gilead Sciences. Other authors: none to declare.
(© 2023 The Author(s).)
| Titel: |
The build-up of stock of stable integrated proviruses overtime explains the difficulty in reducing HIV-1 DNA levels when treatment is initiated at the chronic stage of the infection.
|
|---|---|
| Autor/in / Beteiligte Person: | Mchantaf, G ; Cheret, A ; Melard, A ; Essat, A ; Gardiennet, E ; Bauer, R ; Charre, C ; Meiffredy, V ; Piroth, L ; Goujard, C ; Meyer, L ; Avettand-Fenoel, V |
| Link: | |
| Zeitschrift: | Journal of virus eradication, Jg. 9 (2023-12-09), Heft 4, S. 100357 |
| Veröffentlichung: | 2020- : [London] : Elsevier Ltd. ; <i>Original Publication</i>: London : Mediscript Ltd., [2015]-, 2023 |
| Medientyp: | academicJournal |
| ISSN: | 2055-6640 (print) |
| DOI: | 10.1016/j.jve.2023.100357 |
| Sonstiges: |
|